Observational educational study assessing efficacy of training of physicians and hypertensive patients treated with Perindopril/Indapamide single pill combination to improve antihypertensive efficacy and treatment compliance

Non-interventional educational multicenter open-label study to assess efficacy of training of the physicians and patients with essential hypertension receiving Perindopril/Indapamide single-pill combination to achieve the target levels of blood pressure and to increase the treatment compliance

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN14315146

Enrollment

2000

Registered

2019-11-18

Start date

2014-11-01

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial hypertension Circulatory System Arterial hypertension

Interventions

This study collects data from patients treated with the drug perindopril arginine 10 mg/indapamide 2.5 mg (alone or in addition to other antihypertensive drugs), according to their doctor’s decision.

in group 2, physicians receive training

in group 3, physicians receive training and patients are trained in self-monitoring of blood pressure. Patient blood pressure, as well as safety, is evaluated at baseline, then 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adult patients (=18 years) 2. Essential hypertension 3. BP > 150 /90 mmHg at the background of the current therapy 4. Physician’s decision to administer Perindopril/Indapamide Single-Pill Combination due to inefficacy of the previous monotherapy or combination therapy and according to the indications 5. Patient’s consent to participate in the study

Exclusion criteria

Exclusion criteria: 1. Secondary hypertension 2. Pregnancy, breast-feeding 3. Severe cardiovascular disease (acute myocardial infarction or acute cerebrovascular accident within the last 6 months) 4. Diabetes mellitus in the stage of decompensation 5. Severe hepatic impairment 6. Renal transplantation 7. Nephrectomy or the presence of a single kidney 8. Hypokalemia or hyperkalemia 9. Chronic alcoholism, abuse of drugs 10. Contraindications for taking indapamide/perindopril arginine 2.5 mg/10mg or individual components 11. History of ACEi/indapamide/sulfonamide intolerance 12. Systemic connective tissue diseases 13. Aortic stenosis 14. Malignant neoplasm 15. Hypersensitivity reactions of any etiology 16. Presence of indapamide 1.25 mg/perindopril 5 mg or indapamide 2.5 mg/ perindopril 10 mg or free combination of its compounds (perindopril/indapamide) in a current therapy

Design outcomes

Primary

Measure	Time frame
Blood pressure (mmHg) at baseline and 3-months	—

Secondary

Measure	Time frame
1. Achievement of target levels of BP 2. Treatment compliance 3. Adverse Event/Adverse Reaction	—

Countries

Russian Federation

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 19, 2026